ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0608

Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients

Elena Heras Recuero1, Antia Garcia Fernandez2, Cristina Gomez-Moreno3, Ivan Ferraz Amaro4, Javier Llorca5 and Miguel A. González-Gay6, 1Hospital Fundacion Jimenez Dias, Madrid, Spain, 2Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 3Fundacion Jiménez Díaz School of Nursing, Madrid, Autonomous University Madrid, Madrid, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, 6Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, Damage Index, Disease Activity, Measurement Instrument, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous variables. We intend to analyze the correlation between SLEDAI-2K and SLE-DAS in patients with systemic lupus erythematosus from central Spain, as well as to identify factors contributing to discordance in disease activity classification.

Methods: Retrospective assessment of 324 SLE patients followed up from 2010 to 2024 at Madrid’s Fundación Jiménez Díaz Hospital (Spain). Data were collected from the patients’ most recent visits and disease activity was evaluated using SLEDAI-2K and SLE-DAS, and discordant classifications between the tools were analyzed.

Results: The number of patients in each disease activity category was as follows: Remission (Clinical SLEDAI-2K =0, n=254 [78.4%] vs. clinical SLE-DAS =0, regardless of serology, and prednisone up to 5 mg/day, n=253 [78.3%]); Low activity (SLEDAI-2K 1-4 and prednisone dose ≤ 5 mg/day, n=42 [13.0%] vs. SLE-DAS >0 and ≤ 2.48 with prednisone dose ≤ 7.5 mg/day, n=14 [4.3%]); Mild activity (SLEDAI-2K 1-4 and prednisone dose > 5 mg/day or score 5-6, n=19 [5.9%] vs. SLE-DAS >0 and ≤ 2.48 with prednisone dose > 7.5 mg/day or score >2.48 and ≤7.64, n=46 [14.2%]); Moderate (SLEDAI-2K 7-12 n=7 [2.2%] vs. SLE-DAS >7.64 and ≤9.9 ,n=3 [0.9%]); Severe SLEDAI-2K > 12 (n=2 [0.6%] vs. SLE-DAS >9.9,n=7 [2.2%]). SLEDAI-2K and SLE-DAS showed strong correlation (ρ=0.970, p< 0.001), with high concordance (linearly weighted Kappa index=0.7715, p< 0.001). Forty-four patients were discordant in terms of disease activity categorization. Of these, 39 were discordant at only one level of disease activity. Notably, in 37 of the 44 cases, SLE-DAS classified patients as having a higher degree of disease activity compared to SLEDAI-2K. Patients with skin and hematological manifestations were more commonly discordant in terms of disease activity.

Conclusion: SLEDAI-2K and SLE-DAS demonstrate a strong correlation and high reproducibility for assessing disease activity in the Spanish population. However, SLE-DAS offers additional information, particularly in patients with hematologic and skin involvement, enabling a more precise evaluation of disease activity in SLE patient.

Supporting image 1Figure 1. Correlation between SLEDAI-2K and SLE-DAS*.

*Strong correlation was observed between both scores (ρ = 0.970, p < 0.001), with high concordance (linearly weighted Kappa index = 0.8004, p < 0.001

Supporting image 2Table 1. Clinical characteristics of 296 patients classified as having remission or low disease activity according to SLEDAI-2K, who were either concordant or discordant when assessed using SLEDAS.

Supporting image 3Table 2. Multivariate analysis to identify predictors of discordant evaluation of disease activity when SLEDAI-2K and SLE-DAS were applied.


Disclosures: E. Heras Recuero: None; A. Garcia Fernandez: None; C. Gomez-Moreno: None; I. Ferraz Amaro: None; J. Llorca: None; M. González-Gay: Amgen, 2, GlaxoSmithKlein(GSK), 6, Novo Nordisk, 6, Otsuka, 5, Sanofi, 2.

To cite this abstract in AMA style:

Heras Recuero E, Garcia Fernandez A, Gomez-Moreno C, Ferraz Amaro I, Llorca J, González-Gay M. Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/strong-correlation-between-sledai-and-sle-das-in-the-spanish-population-assessment-of-discordant-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/strong-correlation-between-sledai-and-sle-das-in-the-spanish-population-assessment-of-discordant-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology